Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cytogen financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩7.4 K
2024-10-28
Market Capitalization
₩180 B
2024-10-28
Revenue
₩10.9 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.2B | 798.9M | 642.7M | 347.8M | 760.8M | 3.2B | 10.9B |
| Cost of goods sold | 435.7M | (213.6M) | (6.6M) | (1.2B) | (829.6M) | 1.6B | 9.5B |
| Gross profit | 836.8M | 1.2B | 804.5M | 1.7B | 1.8B | 2.6B | 1.7B |
| Gross profit margin, % | 149.5% | 125.2% | 482.4% | 234.9% | 80.1% | 15.1% | |
| Operating expense total | 3.0B | 4.5B | 6.2B | 13.3B | 12.3B | 11.5B | 12.1B |
| Depreciation and amortization | 452.3M | 976.7M | 1.0B | 1.1B | 795.3M | 5.1B | 3.5B |
| EBITDA | (2.1B) | (3.3B) | (5.4B) | (11.6B) | (10.5B) | (8.9B) | (10.4B) |
| EBITDA margin, % | -416.8% | -838.5% | -3341.8% | -1380.8% | -279.7% | -95.7% | |
| EBIT | (2.6B) | (4.3B) | (6.6B) | (12.7B) | (11.3B) | (14.0B) | (14.0B) |
| EBIT margin, % | -539.5% | -1023.5% | -3664.5% | -1485.4% | -439.2% | -128.6% | |
| Interest income | 9.3M | 295.3M | 239.2M | 224.8M | 521.6M | 216.6M | 1.6B |
| Interest expense | 8.7M | 47.4M | 222.0M | 2.7B | 3.9B | 3.0B | 2.1B |
| Pre tax profit | (2.6B) | (4.1B) | (5.0B) | (13.3B) | (18.7B) | (16.2B) | (17.9B) |
| Income tax expense | (121.1M) | (2.5B) | 79.6M | (409.8M) | (815.1M) | ||
| Net Income | (2.6B) | (4.1B) | (4.9B) | (10.9B) | (18.8B) | (15.8B) | (17.1B) |